Psychoeducational Groups for Adults With Attention-Deficit Hyperactivity/Impulsivity Disorder (ADHD): a Randomized Waitlist-controlled Multicenter Pilot Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Attention Deficit Hyperactivity Disorder
- Sponsor
- Norwegian University of Science and Technology
- Enrollment
- 46
- Locations
- 2
- Primary Endpoint
- Change in patient satisfaction
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This pilot study aims to assess patient satisfaction and preliminary efficacy of a psychoeducational group treatment, using a randomized waitlist-controlled trial, at two different outpatient clinics in mid-Norway. All participants will receive standard treatment during the intervention period. Assessment of client satisfaction (CSQ 8), general self-efficacy (GSE-6), ADHD-related quality of life (AAQoL) symptoms of ADHD (SCL-9; ASRS), and work participation will be conducted at time of recruitment prior to randomization (T0), pre- (T1), post-treatment (T2), with a 10 week follow-up.
Investigators
Eligibility Criteria
Inclusion Criteria
- •confirmed ADHD diagnosis
- •speaking a Scandinavian language
Exclusion Criteria
- •not able or willing to give informed consent
- •psychosis
- •severe learning difficulties
Outcomes
Primary Outcomes
Change in patient satisfaction
Time Frame: Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)
Measured with a modified version of the Client Satisfaction Questionnaire (CSQ-8). The scale consists of 8 items measured on a scale from 1 to 4. A sum score between 8 and 32 indicate the level of satisfaction with services provided.
Change in general self-efficacy
Time Frame: Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)
Measured with General Self-Efficacy Scale (GSE-6), a short-form measure of self-efficacy. Self-efficacy is regarded as a protective factor in adapting to stress and chronic illness. The scale consists of 6 items, measured on a 4-point scale, with a possible range of 6-24.
Secondary Outcomes
- Change in ADHD-related symptoms (ASRS)(Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks))
- Change in ADHD-related symptoms (SCL-9)(Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks))
- Change in ADHD-related quality of life(Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks))